IMPORTANT SAFETY INFORMATION
AFSTYLA®, Antihemophilic Factor (Recombinant), Single Chain, is used to treat and control bleeding episodes in people with hemophilia A. Used regularly (prophylaxis), AFSTYLA can reduce the number of bleeding episodes and the risk of joint damage due to bleeding. Your doctor might also give you AFSTYLA before surgical procedures.
AFSTYLA is administered by intravenous injection into the bloodstream, and can be self-administered or administered by a caregiver. Your healthcare provider or hemophilia treatment center will instruct you on how to do an infusion. Carefully follow prescriber instructions regarding dose and infusion schedule, which are based on your weight and the severity of your condition.
Do not use AFSTYLA if you know you are allergic to any of its ingredients, or to hamster proteins. Tell your healthcare provider if you previously had an allergic reaction to any product containing Factor VIII (FVIII), or have been told you have inhibitors to FVIII, as AFSTYLA might not work for you. Inform your healthcare provider of all medical conditions and problems you have, as well as all medications you are taking.
Immediately stop treatment and contact your healthcare provider if you see signs of an allergic reaction, including a rash or hives, itching, tightness of chest or throat, difficulty breathing, lightheadedness, dizziness, nausea, or a decrease in blood pressure.
Your body can make antibodies, called inhibitors, against FVIII, which could stop AFSTYLA from working properly. You might need to be tested for inhibitors from time to time. Contact your healthcare provider if bleeding does not stop after taking AFSTYLA.
In clinical trials, dizziness and allergic reactions were the most common side effects. However, these are not the only side effects possible. Tell your healthcare provider about any side effect that bothers you or does not go away.
Please see full prescribing information for AFSTYLA, including patient product information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You can also report side effects to CSL Behring's Pharmacovigilance Department at 1-866-915-6958.
ABOUT THE PROGRAMS
The AFSTYLA educational webinar programs, which allow you to join from the comfort of your own home, are for the hemophilia A community. These programs feature a presentation from a trained nurse and stories from an AFSTYLA Patient Advocate.**
These LIVE educational webinar programs offer the hemophilia A community the opportunity to:
- • Learn from a trained nurse about living with and treating hemophilia A
- • Hear from a Patient Advocate as they share their experience and journey to AFSTYLA
- • Discover resources and tools available from CSL Behring
- • Ask questions and gain support from others in the hemophilia A community
For questions or to register over the phone, please contact: 1-866-992-9940 or Support@CommonConnectionsHemA.com.
*Children are welcome to attend! However, anyone under 18 years of age must be accompanied by a parent or caregiver.
**Patient Advocates are not healthcare professionals or medical experts. For medical questions, patients should contact their healthcare provider. Advocates are compensated by CSL Behring LLC for their time and/or expenses.